Ten years-experience of sunitinib in the treatment of advanced pan-NETs: an update on safety profile.

Till now, sunitinib continues to be one of the main therapeutic options for patients with well differentiated advanced panNETs, potentially covering any line of treatment. Therefore, tolerability plays a crucial role to increase adherence to therapy and maximize QoL.